Trial · NCT01323205
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia
NCT01323205, Phase 2, Completed, Janssen Research & Development, LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia. Trials, record NCT01323205. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01323205
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia
- NCT number
- NCT01323205
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 100 participants, actual
- Lead sponsor
- Janssen Research & Development, LLC
- Conditions
- Schizophrenia
- Interventions
- JNJ-40411813, JNJ-40411813, Placebo, Antipsychotic medication
- First posted
- 2011-03-25
- Last updated
- 2014-05-30
- Other registries' IDs
- eudract:2010-023369-23
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Udvalg for Klinische Undersogelser (UKU) ratings for side effects reported by patients | Up to 12 weeks | |
| Primary | The number of patients with abnormal results from clinical laboratory tests performed as a measure of safety and tolerability | Up to 12 weeks | |
| Primary | The number of patients with abnormal results from electrocardiograms (ECGs) performed as a measure of safety and tolerability | Up to 12 weeks | |
| Primary | The number of patients with abnormal results from physical examinations (including vital signs measurements) performed as a measure of safety and tolerability | Up to 12 weeks | |
| Primary | Number of patients with adverse events reported as a measure of safety and tolerability | Up to 12 weeks | |
| Secondary | Positive and Negative Syndrome Scale (PANSS) scores to explore potential therapeutic effect of study drug | Up to 12 weeks | |
| Secondary | Clinical Global Impression - Schizophrenia (CGI-SCH) ratings to explore potential therapeutic effect of study drug | Up to 12 weeks | |
| Secondary | Subjective Well-being under Neuroleptics Scale (SWN) scores to explore potential therapeutic effect of study drug | Up to 12 weeks | |
| Secondary | Plasma (blood) concentration of JNJ-40411813 | Up to 12 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01323205
GET https://conductscience.org/api/trials/v1/NCT01323205/registered